Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.4400 (-0.73%) ($5.2400 - $5.7900) on Wed. Nov. 21, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.57% (three month average) | RSI | 27 | Latest Price | $5.4400(-0.73%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -0.7% a day on average for past five trading days. | Weekly Trend | ADAP declines -10.4% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(16%) GDXJ(11%) JETS(11%) ICLN(9%) SHY(9%) | Factors Impacting ADAP price | ADAP will decline at least -2.785% in a week (0% probabilities). XLP(-10%) XLV(-8%) VIXM(-8%) IFRA(-7%) VXX(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.785% (StdDev 5.57%) | Hourly BBV | 0 () | Intraday Trend | -1.1% | | | |
|
1 - 5 Day Possible Target | $-9.7(-278.31%) | Resistance Level | $6.15 | 5 Day Moving Average | $5.5(-1.09%) | 10 Day Moving Average | $5.81(-6.37%) | 20 Day Moving Average | $6.15(-11.54%) | To recent high | -61.6% | To recent low | 0.2% | Market Cap | $841m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |